Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Commentary Free access | 10.1172/JCI14004

VacA pores as portable portals for urea

Juanita L. Merchant

Internal Medicine and Physiology, University of Michigan, 1150 West Medical Center Drive, MSRB I, Room 3510, Ann Arbor, Michigan 48109-0650, USA.

Phone: (734) 647-2944; Fax: (734) 936-1400; E-mail: merchanj@umich.edu.

Find articles by Merchant, J. in: JCI | PubMed | Google Scholar

Published September 15, 2001 - More info

Published in Volume 108, Issue 6 on September 15, 2001
J Clin Invest. 2001;108(6):803–804. https://doi.org/10.1172/JCI14004.
© 2001 The American Society for Clinical Investigation
Published September 15, 2001 - Version history
View PDF

The epithelial linings of various organs have evolved to shield us from harmful aspects of our environment. In the stomach, the epithelial lining provides a reliable barrier against ingested microbes and toxins, in part by secreting copious amounts of gastric acid, whose major function is to sterilize the stomach contents (1). Whereas most microorganisms, peptides, and toxins cannot survive the low pH of the human stomach, the gastric epithelium has evolved to tolerate this environment, as have certain gastric bacteria, not all of which are benign.

Ulceration of the gastric mucosa was long attributed to excessive acid secretion triggered by stress, and the contribution of microorganisms was overlooked. More recently, it has been revealed that ulcers, like so many other diseases to which humans succumb, are primarily an infectious disorder (2). Nearly 20 years ago, when this hypothesis was confirmed (3), the idea that bacterial infection causes ulcers was considered heresy since no one believed that any organism could survive a pH less than 2. Warren and Marshall clearly demonstrated, however, that Helicobacter pylori thrives at low pH, and this bacterium is now known to be the major mechanism by which ulcers of the upper gastrointestinal tract are induced.

The question that remains unanswered is how H. pylori stimulates acid secretion and induces chronic gastritis. Initial studies identified several bacterial gene products that either are required for the organism to colonize and survive at low pH or might trigger inflammation in the infected stomach. VacA, a toxin expressed by most clinical isolates of H. pylori, meets both criteria. Coincubation of recombinant VacA protein with gastric cell lines induces vacuole formation in the cytoplasm (4), and VacA-expressing strains appear to colonize the stomach more efficiently (5). However, isogenic vacA mutants can colonize and trigger gastritis in both gnotobiotic piglets and Mongolian gerbils (6, 7). Thus, while VacA is clearly a type of virulence factor, it does not appear to be absolutely required for H. pylori virulence.

VacA is expressed as a 140-kDa precursor that is processed to a functional 94-kDa toxin. Following export and exposure to acid, this toxin assembles spontaneously into oligomers. Three domains are required for its activity: a 33–amino acid N-terminal signal sequence, which is cleaved from the mature protein but is required to direct the toxin to the periplasm; an N-terminal 37-kDa region, which contains the vacuolating activity; and a C-terminal 58-kDa region, which is required for binding of the protein to target cell membranes (8). Polymorphisms in VacA account for much of the variation among clinical isolates that can be distinguished antigenically (9). Numerous reports correlate the different isoforms of VacA with virulence. In contrast, another major H. pylori virulence factor, CagA, requires accessory factors expressed from the cag pathogenicity island to mediate its attack on cells. Several studies have now reported that CagA is translocated into the cytoplasm by a type IV secretory apparatus and is subsequently phosphorylated by host cell factors (10–13).

In this issue of the JCI, Tombola and colleagues report a specific function for VacA in the pathogenesis of stomach ulcers (14). They show here that H. pylori VacA binds preferentially to the apical plasma membrane, permeabilizing the host cell to urea. VacA therefore acts as a low pH–activated transmembrane pore. In addition to allowing the transport of neutral solutes, it may also allow the transport of electrolytes and therefore compromise the ability of the host cell to regulate its intracellular environment. While this process is toxic to the host epithelial cell, as evidenced by vacuole formation, VacA provides the bacterium with a competitive advantage by increasing the availability of urea. This metabolite can be converted to ammonia by the cytoplasmic enzyme urease in a reaction regulated by the proton-gated urea channel UreI. Because the accumulation of ammonia increases the buffering capacity within the periplasmic space (15), it appears that VacA improves the efficiency of a pH-sensitive homeostatic mechanism.

Unlike CagA, which requires an elaborate pore-forming structure to traverse the lipid bilayer, VacA can form pores in lipid bilayers autonomously, which classifies the toxin as a type V autotransporter pore (16). A common mechanism for pathogens that damage target cells without direct bacterial invasion is the ability to produce factors that punch holes through the host cell membrane, either by acting alone or by assembling a multi-subunit apparatus (16). These structures permit the flow of solutes from the environment through the outer and inner membranes of the bacteria, but they also disrupt the ability of the target cell to maintain integrity and homeostasis. Whether this is advantageous to the bacterium is unclear, since in many instances, the loss of cell integrity eventually cripples the cell. In response, the injured cell secretes chemokines that activate immune cells to attack the luminal pathogen.

Studies of Helicobacter infection in T or B cell–deficient mice show that Th1 cells, but not B lymphocytes, are required for the onset of gastritis (17, 18). Therefore, analogous to inflammatory bowel disease, which primarily affects the small and large bowels, smoldering inflammation in the stomach also appears to be responsible for the chronic tissue damage and neoplastic sequelae. Loss of differentiated cell types such as parietal and chief cells after months to years of cohabitation with the organism eventually compromises the stomach’s capacity to secrete acid and leads to a rise in gastric pH.

It is not obvious how loss of parietal cells and the eventual rise in gastric pH might benefit the bacteria. Although this has not been tested directly, it seems unlikely that H. pylori can colonize the gastric epithelium efficiently in the absence of acid (15, 19). Reduced colonization may be due to insufficient gastric acid to counterbalance the ammonia produced by the organism. Moreover, with a rise in pH, the stomach is at risk of colonization by less fastidious bacterial species, which may then out-compete H. pylori (20, 21). Thus, in the end, H. pylori may merely be the trigger for a cascade of events that is sustained by the immune system and by repopulation of the stomach by organisms other than H. pylori.

While most H. pylori strains express vacA, there is poor correlation of vacA status with clinical disease and outcome in non-US populations (22, 23). Asian and other non-Western populations make up a large proportion of the world’s population infected with H. pylori (∼50%). Moreover, in vitro studies demonstrate that VacA protein is not required to induce an inflammatory response and colonize animal models (6, 24), implying that non-VacA H. pylori strains must be able to transport urea effectively to survive in the acidic stomach. Since vacA mutants obviously still colonize the normal acid-secreting stomach, it may be that other pore-forming molecules perform an analogous function in these strains (25). The identification of other such proteins may be needed for vaccine development, since it is probable that targeting VacA alone will not generate a universal vaccine (26). Rather, a cocktail of multiple H. pylori–specific factors will likely be required.

Footnotes

See the related article beginning on page 929.

References
  1. Gray, JD, Shiner, M. Influence of gastric pH on gastric and jejunal flora. Gut 1967. 8:74-81.
    View this article via: PubMed Google Scholar
  2. Blaser, MJ. The bacteria behind ulcers. Sci Am 1996. 274:104-107.
    View this article via: PubMed Google Scholar
  3. Marshall, BJ, Warren, JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984. 1:1311-1315.
    View this article via: PubMed Google Scholar
  4. Cover, TL, Blaser, MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 1992. 267:10570-10575.
    View this article via: PubMed Google Scholar
  5. Salama, NR, Otto, G, Tompkins, L, Falkow, S. Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect Immun 2001. 69:730-736.
    View this article via: PubMed CrossRef Google Scholar
  6. Eaton, KA, Cover, TL, Tummuru, MK, Blaser, MJ, Krakowka, S. Role of vacuolating cytotoxin in gastritis due to Helicobacter pylori in gnotobiotic piglets. Infect Immun 1997. 65:3462-3464.
    View this article via: PubMed Google Scholar
  7. Wirth, HP, Beins, MH, Yang, M, Tham, KT, Blaser, MJ. Experimental infection of Mongolian gerbils with wild-type and mutant Helicobacter pylori strains. Infect Immun 1998. 66:4856-4866.
    View this article via: PubMed Google Scholar
  8. de Bernard, M, et al. Identification of the Helicobacter pylori VacA toxin domain active in the cell cytosol. Infect Immun 1998. 66:6014-6016.
    View this article via: PubMed Google Scholar
  9. Atherton, JC, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995. 270:17771-17777.
    View this article via: PubMed CrossRef Google Scholar
  10. Asahi, M, et al. Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med 2000. 191:593-602.
    View this article via: PubMed CrossRef Google Scholar
  11. Backert, S, et al. Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus. Cell Microbiol 2000. 2:155-64.
    View this article via: PubMed CrossRef Google Scholar
  12. Odenbreit, S, et al. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000. 287:1497-1500.
    View this article via: PubMed CrossRef Google Scholar
  13. Stein, M, Rappuoli, R, Covacci, A. Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci USA 2000. 97:1263-1268.
    View this article via: PubMed CrossRef Google Scholar
  14. Tombola, F, et al. The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia. J Clin Invest 2001. 108:929-937.
    View this article via: JCI PubMed CrossRef Google Scholar
  15. Meyer-Rosberg, K, Scott, DR, Rex, D, Melchers, K, Sachs, G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996. 111:886-900.
    View this article via: PubMed CrossRef Google Scholar
  16. Henderson, IR, Nataro, JP. Virulence functions of autotransporter proteins. Infect Immun 2001. 69:1231-1243.
    View this article via: PubMed CrossRef Google Scholar
  17. Smythies, LE, et al. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 2000. 165:1022-1029.
    View this article via: PubMed Google Scholar
  18. Lohoff, M, Rollinghoff, M, Sommer, F. Helicobacter pylori gastritis: a Th1 mediated disease? J Biotechnol 2000. 83:33-36.
    View this article via: PubMed CrossRef Google Scholar
  19. Eaton, KA, Krakowka, S. Avirulent, urease-deficient Helicobacter pylori colonizes gastric epithelial explants ex vivo. Scand J Gastroenterol 1995. 30:434-437.
    View this article via: PubMed CrossRef Google Scholar
  20. Mowat, C, et al. Omeprazole, helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology 2000. 119:339-347.
    View this article via: PubMed CrossRef Google Scholar
  21. Sanduleanu, S, Jonkers, D, De Bruine, A, Hameeteman, W, Stockbrugger, RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 2001. 15:379-388.
    View this article via: PubMed CrossRef Google Scholar
  22. Shimoyama, T, et al. VacA seropositivity is not associated with the development of gastric cancer in a Japanese population. Eur J Gastroenterol Hepatol 1999. 11:887-890.
    View this article via: PubMed CrossRef Google Scholar
  23. Yamaoka, Y, et al. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol 1999. 37:2274-2279.
    View this article via: PubMed Google Scholar
  24. Mitsuno, Y, et al. Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells. Gut 2001. 49:18-22.
    View this article via: PubMed CrossRef Google Scholar
  25. Hancock, RE, Alm, R, Bina, J, Trust, T. Helicobacter pylori: a surprisingly conserved bacterium. Nat Biotechnol 1998. 16:216-217.
    View this article via: PubMed CrossRef Google Scholar
  26. Del Giudice, G, Covacci, A, Telford, JL, Montecucco, C, Rappuoli, R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001. 19:523-563.
    View this article via: PubMed CrossRef Google Scholar
Version history
  • Version 1 (September 15, 2001): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts